Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Titel:
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Auteur:
Löwenberg, Bob Pabst, Thomas Maertens, Johan Gradowska, Patrycja Biemond, Bart J. Spertini, Olivier Vellenga, Edo Griskevicius, Laimonas Tick, Lidwine W. Jongen-Lavrencic, Mojca van Marwijk Kooy, Marinus Vekemans, Marie-Christiane van der Velden, Walter J.F.M. Beverloo, Berna Michaux, Lucienne Graux, Carlos Deeren, Dries de Weerdt, Okke van Esser, Joost W.J. Bargetzi, Mario Klein, Saskia K. Gadisseur, Alain Westerweel, Peter E. Veelken, Hendrik Gregor, Michael Silzle, Tobias van Lammeren-Venema, Daniëlle Moors, Ine Breems, Dimitri A. Hoogendoorn, Mels Legdeur, Marie-Cecile J.C. Fischer, Thomas Kuball, Juergen Cornelissen, Jan Porkka, Kimmo Juliusson, Gunnar Meyer, Peter Höglund, Martin Gjertsen, Bjorn T. Janssen, Jeroen J.W.M. Huls, Gerwin Passweg, Jakob Cloos, Jacqueline Valk, Peter J.M. van Elssen, Catharina H.M.J. Manz, Markus G. Floisand, Yngvar Ossenkoppele, Gert J.